""Today it may be childhood vaccines or mRNA, but tomorrow it's everything," Noubar Afeyan, co-founder and chairman of Moderna, maker of mRNA vaccines, said. "We have to say not just 'why is this happening?,' but 'Where will it stop?'""
""With the pressure on vaccination, I cannot foresee flu vaccination increasing in this country over the next three years," he said in a presentation."
""It's clear this administration has a particular sensitivity around vaccination, and indeed pediatric vaccination," Hudson said. "I'm asked all the time 'what are you going to do to fix this?,' and the truth is we just need to stay extremely objective and continue presenting the evidence. There's really very little else we can do," except wait for the midterm elections, he said."
""There is also a lot of plaintiffs' playbook there," Bourla said. "Everybody will start litigating.""
Pharmaceutical executives report increasing concern that anti-vaccine rhetoric and politicized statements are eroding public confidence and reducing vaccination rates, including seasonal flu shots during a bad flu season. Company leaders expect short-term declines in vaccine coverage and advise sustained, objective presentation of scientific evidence while awaiting political changes such as midterm elections. Executives warn that public figures without scientific backgrounds can profit from lawsuits and that allies may pursue legal action against drugmakers. Companies anticipate elevated litigation risk and emphasize maintaining a long-term focus on vaccine development and coverage despite misinformation on social platforms and statements from prominent individuals.
Read at Ars Technica
Unable to calculate read time
Collection
[
|
...
]